Intensive Care Unit and Secondary and Primary Immune Deficiency

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

16 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-01-31

Study Completion Date

2019-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Primary immune deficiencies (PID) are characterized by a failure of the immune system that is not explained by any infectious, neoplastic, or iatrogenic cause. In 2015, more than 300 different inherited rare disorders were described. The occurrence of PID in adult is rare and diagnosis may be supported by the 6 ESID signs for adult. However these warnings signs are based only on expert recommendations and do not include comprehensive symptoms of PIDs. Recurrent infections, more aggressive, are the most common mode of revelation of the PID. Less frequently, autoimmune manifestation, solid tumor, lymphoproliferation tumor, chronic granulomatosis or hemophagocytic lymphohistiocytosis syndrome (HLS) may also revealed a PID. The objective of this study was to evaluate the occurrence of unknown PID in adult admitted in critical care unit and to determinate if the investigation of PID in patients with severe infections or HLS should be routinely performed in MCIU.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Populations at Risk of Developing Chronic Hepatitis Linked to Chronic Enteric Virus Infection in Patients With Primary Immunodeficiency and Secondary Humoral Deficiency

NCT06659588

Humoral Primary Immunodeficiencies (PIDs) Secondary Form of Humoral Immunodeficiencies Combined Immunodeficiency (CID) +1 more

RECRUITING

Participation in a Research Registry for Immune Disorders

NCT01953016

Primary Immunodeficiencies APECED CGD +2 more

COMPLETED

Detection and Characterization of Host Defense Defects

NCT00001355

Immune Defects

RECRUITING

Severe PID With Lymphoproliferation and Neutropenia

NCT03427593

Primary Immune-Deficiency (PID) Common Variable Immune Deficiency (CVID)

COMPLETED NA

Evaluation of Patients With Immune Function Abnormalities

NCT00128973

Chronic Granulomatous Disease (CGD) X-Linked Severe Combined Immune Deficiency (XSCID) Leukocyte Adhesion Deficiency 1 (LAD) +1 more

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Primary Immune Deficiency Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Internal Medicine consultation

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged 18-65
* Hospitalized in medical intensive care unit for :
* Severe infection without pathogen identification
* Severe infection due to encapsuled pathogen
* Opportunistic infections or unusual pathogen
* Idiopathic hemophagocytic syndrome

Exclusion Criteria

* primary immunodeficiency already known
* secondary immunodeficiency already known (HIV, cancer, immunosuppressive or immunomodulatory treatment, nephrotic syndrome, protein-losing enteropathy, severe malnutrition before admission, cirrhosis with hepatic failure, sickle cell disease, splenectomy and moderate chronic renal failure (clearance between 30 and 59 m² min/1.73 ml)
* local-regional factors which can be responsible for infections (history of ear, nose and throat surgery or neurosurgery, history of fracture of the skull base, cystic fibrosis, chronic respiratory insufficient)

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No